Loading stock data…
BioXcel Therapeutics (BTAI)
$0.07
Market ClosedLast close Sep 4
BioXcel Therapeutics, Inc., together with its subsidiary, OnkosXcel Therapeutics LLC, operates as a biopharmaceutical company that utilizes artificial intelligence approaches to develop medicines in neuroscience and immuno-oncology in the United States.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
BioXcel Therapeutics, Inc. in the Healthcare sector is trading at $0.07 with a market capitalization of $36M. The stock is currently near its 52-week low of $0.07, remaining 94.5% below its 200-day moving average. On fundamentals, Piotroski 3/9 flags weak fundamentals, Altman Z in the distress zone. Risk note: RSI 9 is oversold, raising the odds of a near-term bounce; MACD remains below its signal line. The Whystock Score of 25/100 signals elevated caution as multiple indicators diverge.
Ecosystem Influences
Long-term trend bearish (price vs 200-day SMA)
Oversold momentum (RSI 9) — potential for technical mean-reversion
Macro-economic sensitivity to interest rate and inflation shifts
Quarterly Financials
| Metric (USD) | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 |
|---|---|---|---|---|---|
| Total Revenue | $206,000↓ | $256,000↑ | $98,000↓ | $120,000↓ | $168,000 |
| Gross Profit | -$77,000↓ | $224,000↑ | $87,000↑ | $13,000↓ | $154,000 |
| Operating Income | -$10.22M↑ | -$10.28M↑ | -$14.03M↑ | -$15.85M↓ | -$10.10M |
| Net Income | -$12.69M↓ | -$12.54M↑ | -$30.91M↓ | -$19.19M↓ | -$7.25M |
Peer Comparison
JNJUNHPFE
Fundamentals
BioXcel Therapeutics, Inc., together with its subsidiary, OnkosXcel Therapeutics LLC, operates as a biopharmaceutical company that utilizes artificial intelligence approaches to develop medicines in neuroscience and immuno-oncology in the United Stat...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$35.66M
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
-
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Elite ROE. Management converts capital into profit efficiently.
71.38%
Volume
Today's trading volume
47.48M
Recent News
Teva (TEVA) Backed a Bid of Up to $125M in Cash Plus Assumed Liabilities for BioXcel’s Assets. Is Bankruptcy-Sale Risk Worth the At-Home Opportunity?
Teva Pharmaceuticals International GmbH, a subsidiary of Teva Pharmaceutical Industries Limited (NYSE:TEVA), agreed to serve as the stalking-horse bidder for substantially all assets of BioXcel Therapeutics, Inc. (NASDAQ:BTAI) and certain affiliates through a court-supervised Chapter 11 auction. Teva Pharmaceutical Industries Limited (NYSE:TEVA) is the parent of the bidder and guarantor of the milestone-payment obligations. The […]
Teva Seeks to Boost Neuroscience Portfolio With BioXcel Asset Bid
TEVA's latest bid for BioXcel assets could expand its neuroscience portfolio with Igalmi and a potential at-home agitation treatment.
Teva makes stalking horse bid for BioXcel assets
The transaction would see Teva obtain worldwide rights to Igalmi and the investigational BXCL501.
Teva Pharmaceuticals to acquire BioXcel assets for up to $125m
The transaction would see Teva obtain worldwide rights to Igalmi and the investigational BXCL501.
What Is Teva Pharmaceutical Industries (TEVA) Gaining From This Bankruptcy Drug Deal?
Teva Pharmaceutical Industries (NYSE:TEVA) agreed to acquire BioXcel Therapeutics' dexmedetomidine sublingual film for at-home treatment of agitation in schizophrenia and bipolar disorder through a bankruptcy asset sale process. The transaction is subject to approval by the bankruptcy court, potential competing bids, and standard closing conditions before Teva can assume full rights to the asset. The dexmedetomidine sublingual film is under FDA review for at-home use. This transaction is...